Hua Jin1, Shizhi Wang2, Yan Zhang2, Xing Zhang2, Haixia Zhu1, Yang Liu3, Jian Cao3, Dake Li3, Bo Ding4, Wenjing Yan2. 1. Clinical Laboratory, Affiliated Tumor Hospital of Nantong University (Nantong Tumor Hospital), Nantong, People's Republic of China. 2. Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, People's Republic of China. 3. Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, People's Republic of China. 4. Department of Gynecology and Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Abstract
BACKGROUND: Cervical cancer (CC) is one of the most common malignant tumors in women, and its treatment is often accompanied by high recurrence. We aimed to identify the long non-coding RNAs (lncRNAs) associated with CC recurrence. METHODS: We downloaded lncRNAs expression data of CC patients from The Cancer Genome Atlas (TCGA) dataset and used Cox regression models to analyze the lncRNAs relationship with CC recurrence. The significantly associated lncRNAs were utilized to construct a recurrence risk score (RRS) model. Bioinformatics analyses were used to assess the potential role of the critical lncRNAs in CC recurrence. The effect of critical lncRNAs on CC phenotype was determined by in vitro experiments. RESULTS: Using Cox regression analysis, four lncRNAs, ie, HCG11, CASC15, LINC00189, and LINC00905, were markedly associated with worse recurrence-free survival (RFS) of CC, whereas three lncRNAs, including HULC, LINC00173, and MIR22HG, were the opposite. After constructing the RRS model, Kaplan-Meier analysis revealed that patients with high RRS had significantly increased risk of recurrence. Among the 20 types of tumors in the TCGA database which all had adjacent normal tissues, MIR22HG and HCG11were significantly downregulated in 18 and 10 types of tumors including CC, respectively. Increased MIR22HG was significantly relevant to decreased risks of recurrence among the subgroups of age at diagnosis < 45 (Hazard Ratio (HR) = 0.26), stage I/II (HR = 0.33), T stage I/II (HR = 0.30), chemotherapy (HR = 0.18), and molecular therapy (HR = 0.16). Functionally, elevated MIR22HG expression could suppress CC cell proliferation, migration and invasion. CONCLUSION: MIR22HG has a fundamental role in CC recurrence and could be served as a potential prognostic biomarker.
BACKGROUND: Cervical cancer (CC) is one of the most common malignant tumors in women, and its treatment is often accompanied by high recurrence. We aimed to identify the long non-coding RNAs (lncRNAs) associated with CC recurrence. METHODS: We downloaded lncRNAs expression data of CC patients from The Cancer Genome Atlas (TCGA) dataset and used Cox regression models to analyze the lncRNAs relationship with CC recurrence. The significantly associated lncRNAs were utilized to construct a recurrence risk score (RRS) model. Bioinformatics analyses were used to assess the potential role of the critical lncRNAs in CC recurrence. The effect of critical lncRNAs on CC phenotype was determined by in vitro experiments. RESULTS: Using Cox regression analysis, four lncRNAs, ie, HCG11, CASC15, LINC00189, and LINC00905, were markedly associated with worse recurrence-free survival (RFS) of CC, whereas three lncRNAs, including HULC, LINC00173, and MIR22HG, were the opposite. After constructing the RRS model, Kaplan-Meier analysis revealed that patients with high RRS had significantly increased risk of recurrence. Among the 20 types of tumors in the TCGA database which all had adjacent normal tissues, MIR22HG and HCG11were significantly downregulated in 18 and 10 types of tumors including CC, respectively. Increased MIR22HG was significantly relevant to decreased risks of recurrence among the subgroups of age at diagnosis < 45 (Hazard Ratio (HR) = 0.26), stage I/II (HR = 0.33), T stage I/II (HR = 0.30), chemotherapy (HR = 0.18), and molecular therapy (HR = 0.16). Functionally, elevated MIR22HG expression could suppress CC cell proliferation, migration and invasion. CONCLUSION: MIR22HG has a fundamental role in CC recurrence and could be served as a potential prognostic biomarker.
Authors: M A Quinn; J L Benedet; F Odicino; P Maisonneuve; U Beller; W T Creasman; A P M Heintz; H Y S Ngan; S Pecorelli Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: William Small; Monica A Bacon; Amishi Bajaj; Linus T Chuang; Brandon J Fisher; Matthew M Harkenrider; Anuja Jhingran; Henry C Kitchener; Linda R Mileshkin; Akila N Viswanathan; David K Gaffney Journal: Cancer Date: 2017-05-02 Impact factor: 6.860
Authors: D Bodurka-Bevers; M Morris; P J Eifel; C Levenback; M W Bevers; K R Lucas; J T Wharton Journal: Gynecol Oncol Date: 2000-08 Impact factor: 5.482
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Didier Ismael May-Hau; Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Vilma Carolina Bekker-Méndez; Fredy Omar Beltrán-Anaya; Elva Jiménez-Hernández; Mónica Patricia Ortíz-Maganda; Francisco Xavier Guerra-Castillo; Aurora Medina-Sanson; Janet Flores-Lujano; Jorge Alfonso Martín-Trejo; José Gabriel Peñaloza-González; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; Gabriela Alicia Hernández-Echáurregui; Rosa Martha Espinosa-Elizondo; María de Lourdes Gutiérrez-Rivera; Rodrigo Sanchez-Hernandez; María Luisa Pérez-Saldívar; Luz Victoria Flores-Villegas; Laura Elizabeth Merino-Pasaye; David Aldebarán Duarte-Rodríguez; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Haydeé Rosas-Vargas; Alfredo Hidalgo-Miranda; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738